Clinical impact of IgG spike antibody titers and dose of tixagevimab-cilgavimab in patients with B-cell malignancies who received tixagevimab-cilgavimab
| . | SARS-CoV-2 negative . | SARS-CoV-2 positive . | P . |
|---|---|---|---|
| IgG spike antibody titer beforetixagevimab-cilgavimab(AU/mL) | 63 | 4 | .1901 |
| Median (range) | 250 (14-800) | 309 (41-643) | |
| ≥264, n (%) | 12 (19) | 2 (50) | |
| <264, n (%) | 51 (81) | 2 (50) | |
| IgG spike antibody titer after totixagevimab-cilgavimab(AU/mL) | 25 | 4 | >.999 |
| Median (range) | 800 (526-800) | 681 (588-800) | |
| ≥264, n (%) | 25 (100) | 4 (100) | |
| <264, n (%) | 0 (0) | 0 (0) | |
| Tixagevimab-cilgavimab dose (mg), n (%) | 224 | 27 | .1804 |
| 150/150 | 11 (5) | 3 (11) | |
| 300/300 | 213 (95) | 24 (88) |
| . | SARS-CoV-2 negative . | SARS-CoV-2 positive . | P . |
|---|---|---|---|
| IgG spike antibody titer beforetixagevimab-cilgavimab(AU/mL) | 63 | 4 | .1901 |
| Median (range) | 250 (14-800) | 309 (41-643) | |
| ≥264, n (%) | 12 (19) | 2 (50) | |
| <264, n (%) | 51 (81) | 2 (50) | |
| IgG spike antibody titer after totixagevimab-cilgavimab(AU/mL) | 25 | 4 | >.999 |
| Median (range) | 800 (526-800) | 681 (588-800) | |
| ≥264, n (%) | 25 (100) | 4 (100) | |
| <264, n (%) | 0 (0) | 0 (0) | |
| Tixagevimab-cilgavimab dose (mg), n (%) | 224 | 27 | .1804 |
| 150/150 | 11 (5) | 3 (11) | |
| 300/300 | 213 (95) | 24 (88) |